| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | EPIDIOLEX (cannabidiol) | Epilepsy with Myoclonic-Atonic Seizures (EMAS) / Doose syndrome | Phase 3 | Ongoing | Oral | Neurology |
| Jazz Pharmaceuticals plc | Defibrotide | VOD in high-risk patients following hematopoietic stem cell transplantation | Phase 3 | Trial Discontinued | Intravenous | Hematology |
| Jazz Pharmaceuticals plc | JZP-110 | Excessive sleepiness associated with obstructive sleep apnea | Phase 3 | Trial Completed | oral | Neurology |
| Jazz Pharmaceuticals plc | Epidiolex (cannabidiol) - (EpiCom) | Tuberous sclerosis complex (TSC)-associated seizures | Phase 3 | Ongoing | oral | Neurology |
| Jazz Pharmaceuticals plc | Cannabidiol oral solution (GWP42003-P) | Treatment-Resistant Epilepsies | Phase 3 | Trial Completed | Oral | Neurology |
| Jazz Pharmaceuticals plc | Suvecaltamide - (JZP-385) | Essential Tremor (ET) | Phase 2b | Data Released | Oral | Neurology |
| Jazz Pharmaceuticals plc | GWP42003 | Schizophrenia | Phase 2b | Ongoing | oral | Psychiatric |
| Jazz Pharmaceuticals plc | Ziihera - (HERIZON-BTC-01) | Biliary tract cancer (BTC) | Phase 2 | Data Released | Oral | Oncology |